Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum

Background and purpose About a quarter of people with epilepsy have intellectual disability (ID). This group has communication issues, premature mortality, more treatment resistance, difficulties in making informed choices and greater risks of physical and mental health comorbidities. There is no sp...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of neurology Vol. 23; no. 7; pp. 1152 - 1157
Main Authors Doran, Z., Shankar, R., Keezer, M. R., Dale, C., McLean, B., Kerr, M. P., Devapriam, J., Craig, J., Sander, J. W.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.07.2016
John Wiley & Sons, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background and purpose About a quarter of people with epilepsy have intellectual disability (ID). This group has communication issues, premature mortality, more treatment resistance, difficulties in making informed choices and greater risks of physical and mental health comorbidities. There is no specific prescribing guidance for this large and vulnerable group. The literature on prescribing for epilepsy in this group was reviewed, in particular examining how antiepileptic drugs (AEDs) work regarding their side effect profiles, effects on specific epilepsy syndromes associated with ID and their individual strengths and weaknesses based on the nature and degree of ID. Method This is a narrative review for which a comprehensive search was conducted to identify evidence for prescribing commonly used AEDs to people with ID including genetic syndromes specifically associated with epilepsy. Results A detailed analysis of the results has highlighted the urgent requirement for suitable and reliable evidence in AED prescribing amongst adults with epilepsy and ID as no studies taking account of the response to AEDs of the ID populations based on the WHO Diagnostic and Statistical Manual of Mental Disorders criteria of clinical severity of ID were identified. Conclusion There is a significant shortfall in suitably powered studies to provide sufficient evidence for safe prescribing of AEDs to people with ID. Click here to view the accompanying paper in this issue.
Bibliography:Janssen-Cilag
UCB Pharma
ArticleID:ENE13016
Sanofi-Synthelabo
Special Products Ltd
Desitin
Pfizer
Eisai
Data S1. The search strategy in detail.Data S2. A table of key papers and their findings.Data S3. Clinical Pearls for prescribing in ID.
ark:/67375/WNG-8ZCJB9GV-F
UCB
istex:ED080FC93E7BE85630641BECAE16B02810E2BC25
GSK
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1351-5101
1468-1331
DOI:10.1111/ene.13016